Clinical trials: open to volunteers, sponsored by Sun Yat-sen University
Nonmetastatic Locally Advanced Non-Clear Cell Renal Cell Carcinoma
Toripalimab and Lenvatinib With or Without SBRT Before Surgery for Non-Clear Cell Kidney Cancer
This single-center, nonrandomized, two-cohort Phase II study will evaluate neoadjuvant toripalimab and lenvatinib with or without stereotactic body radiotherapy (SBRT) in patients with resectable, nonmetastatic locally advanced…
- Trial name
- TL-SBRT-nccRCC (NCT07922928)
- Testing
- Toripalimab, Lenvatinib, Stereotactic Body Radiotherapy
- Volunteers
- 36 people
- Sponsor
- Sun Yat-sen University
Liver Cirrhosis, Gastroesophageal Varices
The Value of Spleen Thickness and Spleen Diameter for Gastroesophageal Varices Diagnosis in Compensated Cirrhosis
This retrospective cross-sectional diagnostic study compared the diagnostic performance of ultrasound-measured spleen thickness (ST) and spleen diameter (SD) against esophagogastroduodenoscopy (EGD) for gastroesophageal varices…
- Trial name
- NCT07920744
- Testing
- spleen diameter, spleen thickness, esophagogastroduodenoscopy (EGD)
- Where
- China
- Volunteers
- 364 people
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
Localized Clear Cell Renal Cell Carcinoma
Pucotenlimab, Lenvatinib, and SBRT Before Surgery for Localized Clear Cell Renal Cell Carcinoma
This single-arm Phase II study will evaluate the efficacy and safety of neoadjuvant pucotenlimab, lenvatinib, and stereotactic body radiotherapy (SBRT) in adults with localized clear cell renal cell carcinoma who are candidates…
- Trial name
- PLS-NEO-RCC (NCT07922915)
- Testing
- Pucotenlimab, Lenvatinib, Stereotactic Body Radiotherapy
- Volunteers
- 24 people
- Sponsor
- Sun Yat-sen University
Radiotherapy, Adjuvant, Phyllodes Breast Tumor
Molecular Subtype-Guided Postoperative Radiotherapy for Phyllodes Tumor of the Breast
Phyllodes tumor (PT) of the breast is a rare fibroepithelial neoplasm, and the role of postoperative radiotherapy (PORT) remains controversial.
- Conditions
- Radiotherapy, Adjuvant, Phyllodes Breast Tumor, Prognosis, Molecular Typing
- Trial name
- NCT07657169
- Testing
- Postoperative Radiotherapy (PORT)
- Where
- 4 sites in China
- Volunteers
- 160 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Colorectal Liver Metastases (CRCLM), Colorectal Neoplasms
RAPID for Unresectable Colorectal Liver Metastases
The goal of this clinical trial is to learn if the RAPID procedure works to treat colorectal cancer that has spread to the liver and cannot be removed by surgery. It will also learn about the safety of the procedure.
- Trial name
- RAPID-uCRLM (NCT07919951)
- Testing
- RAPID Procedure
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Bladder Cancer
DV Plus Toripalimab With Cetirizine and Mecobalamin Pretreatment in Patients With Locally Advanced Unresectable or Metastatic Bladder Cancer
This is a prospective, open-label, single-arm exploratory clinical study evaluating the efficacy and safety of disitamab vedotin (RC48) plus toripalimab with cetirizine and mecobalamin in patients with locally advanced…
- Trial name
- NCT07853053
- Testing
- Disitamab Vedotin, Toripalimab, Cetirizine
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Squamous Cell Carcinoma of Head and Neck (SCCHN)
Becotatug Vedotin Plus Pucotenlimab in Locally Advanced Head and Neck Squamous Cell Carcinoma With Suboptimal Response to Induction Immunochemotherapy
Patients with locally advanced head and neck squamous cell carcinoma (HNSCC) may receive chemotherapy combined with immunotherapy before surgery to reduce tumor size.
- Trial name
- NCT07915258
- Testing
- Becotatug Vedotin (MRG003), Pucotenlimab
- Where
- 4 sites in China
- Volunteers
- 22 people
- Sponsor
- Sun Yat-sen University
Cancer, Precancerous Lesion
Performance of Multi-Cancer Detection Test in Asymptomatic Patients With Neoplastic Lesions
This multicenter, observational case-only study will evaluate the clinical performance of a blood-based, cell-free DNA (cfDNA) methylation multi-cancer early detection (MCED) test in adults aged 50 to 74 years with confirmed…
- Conditions
- Cancer, Precancerous Lesion, Carcinoma in Situ
- Trial name
- NCT07915271
- Testing
- MCED
- Volunteers
- 948 people
- Sponsor
- Sun Yat-sen University
Oral Mucositis (Ulcerative) Due to Radiation, Nasopharyngeal Carcinoma (NPC)
Taurine for the Prevention and Treatment of Radiation-induced Oral Mucositis in Patients With Nasopharyngeal Carcinoma
This clinical trial aims to understand whether taurine can prevent and reduce severe radiation-induced oral mucositis in patients with nasopharyngeal carcinoma undergoing radiotherapy.
- Trial name
- NCT07567742
- Testing
- Taurine
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Sun Yat-sen University
Prostate Cancer (Adenocarcinoma)
Deutenzalutamide and Hormone Therapy Before and After Surgery With Docetaxel Before Surgery for High-Risk Localized or Locally Advanced Prostate Cancer
This study will assess the effects and safety of deutenzalutamide combined with hormone therapy before and after prostate cancer surgery, with docetaxel chemotherapy added before surgery.
- Trial name
- NCT07907653
- Testing
- Deutenzalutamide, Docetaxel, ADT
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Malignant Phyllodes Tumor of the Breast
Dynamic ctDNA Monitoring in Advanced Malignant Phyllodes Tumors of the Breast
Malignant phyllodes tumor of the breast is a rare fibroepithelial tumor. Patients with metastatic or unresectable disease have limited systemic treatment options, and there remains a need for biomarkers that can dynamically…
- Trial name
- NCT07903181
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Nasopharyngeal Carcinoma (NPC)
Becotatug Vedotin Plus Gemcitabine and a PD-1 Inhibitor in Recurrent or Metastatic Nasopharyngeal Carcinoma
This is a single-center, single-arm, phase II clinical trial designed to evaluate the efficacy and safety of becotatug vedotin combined with gemcitabine and a PD-1 inhibitor as second-line or later treatment for patients with…
- Trial name
- NCT07902713
- Testing
- Becotatug Vedotin (MRG003), Gemcitabine (1000 mg/m2), Camrelizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Non-Clear Cell Renal Cell Carcinoma (nccRCC)
A Phase III Randomized Controlled Trial of Serplulimab Plus Fruquintinib as Adjuvant Therapy for High-Risk Non-Clear Cell Renal Cell Carcinoma
People with non-clear cell renal cell carcinoma may remain at high risk of cancer recurrence even after surgery has removed all visible disease.
- Trial name
- SerF-ADJ (NCT07904156)
- Testing
- Serplulimab + Fruquintinib
- Volunteers
- 108 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Cancinoma (NPC)
Risk-Adapted Anlotinib and PD-L1 for Locoregionally Advanced Nasopharyngeal Carcinoma
The purpose of this study is to evaluate the efficacy and safety of a risk-adapted treatment strategy incorporating induction therapy (Gemcitabine + Cisplatin) with Anlotinib plus Benmelstobart, followed by treatment allocation…
- Trial name
- RAPID (NCT07904819)
- Testing
- Anlotinib Hydrochloride Capsules, Benmelstobart, Gemcitabine (GEM)
- Volunteers
- 214 people
- Sponsor
- Sun Yat-sen University
Systemic Health Risk
AI-Assisted Systemic Health Risk Assessment in General Ophthalmology
This study will evaluate whether providing ophthalmologists with additional artificial intelligence (AI)-assisted health risk information derived from routine retinal images affects subsequent clinical care in adults attending…
- Trial name
- LifeEye-RCT (NCT07890922)
- Testing
- AI-Assisted Health Risk Information
- Where
- China
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Endometrial Cancer
A Preliminary Exploratory Study of Cadonilimab Combined With Progestin for Fertility-Sparing Treatment in Early Endometrial Cancer
This is a single-center, prospective, open-label, single-arm exploratory phase II study evaluating the efficacy and safety of cadonilimab combined with megestrol acetate as fertility-sparing treatment for patients with…
- Trial name
- NCT07900256
- Testing
- Cadonilimab, Megestrol Acetate (MA), Levonorgestrel-releasing intrauterine system
- Volunteers
- 10 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Radiation Induced Proctitis
Fecal Microbiota Transplantation for Radiation-Induced Proctopathy
The goal of this single-arm trial is to learn if Fecal Microbiota Transplantation (FMT) works to treat hemorrhagic radiation-induced proctopathy.
- Trial name
- NCT06776029
- Testing
- Fecal Microbiota Transplantation Capsule
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Hepato Cellular Carcinoma (HCC)
TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. The recurrence rate after curative resection for early-stage HCC remains extremely high, with 2-year and 5-year recurrence rates…
- Trial name
- ACTION-001 (NCT07487662)
- Testing
- sintilimab, ipilimumab N01, Lenvatinib
- Where
- China
- Volunteers
- 105 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer
Dynamic Plasma EBV DNA-Guided Risk-Adapted Treatment With Becotatug Vedotin (MRG003) Plus PD-1 Blockade in Locoregionally Advanced Nasopharyngeal Carcinoma
The purpose of this study is to evaluate the efficacy and safety of a risk-adapted treatment strategy incorporating induction therapy with becotatug vedotin (MRG003) plus pucotenlimab, followed by treatment allocation based on…
- Trial name
- NCT07524413
- Testing
- Becotatug Vedotin, Pucotenlimab, Intensity-Modulated Radiotherapy
- Volunteers
- 298 people
- Sponsor
- Sun Yat-sen University
Newly Diagnosed Glioblastoma, MGMT-Unmethylated Glioblastoma
A Single-Arm, Open-Label, Multicenter Clinical Study of Teniposide Combined With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma (nGBM) With MGMT Promotor Region Unmethylated
The Primary Objective of this study is to evaluate the efficacy and safety of teniposide in combination with temozolomide for the treatment of newly diagnosed glioblastoma (nGBM) with MGMT promotor region unmethylated.
- Trial name
- NCT07894549
- Testing
- Teniposide Combined with Temozolomide
- Volunteers
- 72 people
- Sponsor
- Sun Yat-sen University